Lauren C Peres1, Sweta Sinha2, Mary K Townsend2, Brooke L Fridley3, Beth Y Karlan4, Susan K Lutgendorf5, Eileen Shinn6, Anil K Sood7, Shelley S Tworoger8. 1. Department of Cancer Epidemiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, United States of America. Electronic address: lauren.peres@moffitt.org. 2. Department of Cancer Epidemiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, United States of America. 3. Department of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, United States of America. 4. Department of Obstetrics and Gynecology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, United States of America. 5. Departments of Psychological and Brain Sciences and Obstetrics and Gynecology, University of Iowa, Iowa City, IA, United States of America. 6. Department of Behavioral Science, University of Texas MD Anderson Cancer Center, Houston, TX, United States of America. 7. Department of Gynecologic Oncology and Reproductive Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, United States of America. 8. Department of Cancer Epidemiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, United States of America; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, United States of America.
Abstract
OBJECTIVE: Although ovarian cancer is a deadly disease, approximately a third of women survive ≥9 years after diagnosis. The factors associated with achieving long-term survival are not well understood. In this study, data from the Surveillance, Epidemiology, and End Results (SEER) program were used to determine predictors of survival trajectories among women with epithelial ovarian cancer and across histotype (high-grade serous carcinoma (HGSC) and non-HGSC). METHODS: Data on 35,868 women diagnosed with epithelial ovarian cancer in 2004-2016 were extracted from SEER. Extended Cox proportional hazards regression was used to estimate overall and histotype-specific associations between patient and tumor characteristics and all-cause mortality within each survival time (t) interval (t < 3, 3 ≤ t < 6, 6 ≤ t < 9, and 9 ≤ t < 13 years). RESULTS: Age at diagnosis, marital status, race/ethnicity, stage, and surgery were more strongly associated with mortality in the short-term survival period, and these associations waned with increasing survival time. Exceptions to this pattern were age >70 years at diagnosis, where a high risk of mortality was observed in both the t < 3 and t ≥ 9 year time periods, and non-Hispanic Asian/Pacific Islanders, where a more pronounced inverse association with mortality was observed in t ≥ 9 years after diagnosis. Similar associations were observed for HGSC, although the waning effect was not apparent for most characteristics. Mortality associations for non-HGSC were more pronounced for stage and race/ethnicity, primarily for non-Hispanic Asian/Pacific Islanders. CONCLUSIONS: Most patient and tumor characteristics were more strongly associated with mortality in the years following diagnosis, but have declining impact with increasing survival time. Given this waning effect, it is critical to identify factors impacting risk of mortality as ovarian cancer patients advance through the survival trajectory.
OBJECTIVE: Although ovarian cancer is a deadly disease, approximately a third of women survive ≥9 years after diagnosis. The factors associated with achieving long-term survival are not well understood. In this study, data from the Surveillance, Epidemiology, and End Results (SEER) program were used to determine predictors of survival trajectories among women with epithelial ovarian cancer and across histotype (high-grade serous carcinoma (HGSC) and non-HGSC). METHODS: Data on 35,868 women diagnosed with epithelial ovarian cancer in 2004-2016 were extracted from SEER. Extended Cox proportional hazards regression was used to estimate overall and histotype-specific associations between patient and tumor characteristics and all-cause mortality within each survival time (t) interval (t < 3, 3 ≤ t < 6, 6 ≤ t < 9, and 9 ≤ t < 13 years). RESULTS:Age at diagnosis, marital status, race/ethnicity, stage, and surgery were more strongly associated with mortality in the short-term survival period, and these associations waned with increasing survival time. Exceptions to this pattern were age >70 years at diagnosis, where a high risk of mortality was observed in both the t < 3 and t ≥ 9 year time periods, and non-Hispanic Asian/Pacific Islanders, where a more pronounced inverse association with mortality was observed in t ≥ 9 years after diagnosis. Similar associations were observed for HGSC, although the waning effect was not apparent for most characteristics. Mortality associations for non-HGSC were more pronounced for stage and race/ethnicity, primarily for non-Hispanic Asian/Pacific Islanders. CONCLUSIONS: Most patient and tumor characteristics were more strongly associated with mortality in the years following diagnosis, but have declining impact with increasing survival time. Given this waning effect, it is critical to identify factors impacting risk of mortality as ovarian cancerpatients advance through the survival trajectory.
Authors: Francisco J Candido-dos-Reis; Honglin Song; Ellen L Goode; Julie M Cunningham; Brooke L Fridley; Melissa C Larson; Kathryn Alsop; Ed Dicks; Patricia Harrington; Susan J Ramus; Anna de Fazio; Gillian Mitchell; Sian Fereday; Kelly L Bolton; Charlie Gourley; Caroline Michie; Beth Karlan; Jenny Lester; Christine Walsh; Ilana Cass; Håkan Olsson; Martin Gore; Javier J Benitez; Maria J Garcia; Irene Andrulis; Anna Marie Mulligan; Gord Glendon; Ignacio Blanco; Conxi Lazaro; Alice S Whittemore; Valerie McGuire; Weiva Sieh; Marco Montagna; Elisa Alducci; Siegal Sadetzki; Angela Chetrit; Ava Kwong; Susanne K Kjaer; Allan Jensen; Estrid Høgdall; Susan Neuhausen; Robert Nussbaum; Mary Daly; Mark H Greene; Phuong L Mai; Jennifer T Loud; Kirsten Moysich; Amanda E Toland; Diether Lambrechts; Steve Ellis; Debra Frost; James D Brenton; Marc Tischkowitz; Douglas F Easton; Antonis Antoniou; Georgia Chenevix-Trench; Simon A Gayther; David Bowtell; Paul D P Pharoah Journal: Clin Cancer Res Date: 2014-11-14 Impact factor: 12.531
Authors: Andrew Berchuck; Joellen M Schildkraut; C Leigh Pearce; Georgia Chenevix-Trench; Paul D Pharoah Journal: Adv Exp Med Biol Date: 2008 Impact factor: 2.622
Authors: Nadia Howlader; Lynn A G Ries; Angela B Mariotto; Marsha E Reichman; Jennifer Ruhl; Kathleen A Cronin Journal: J Natl Cancer Inst Date: 2010-10-11 Impact factor: 13.506
Authors: John R McLaughlin; Barry Rosen; Joel Moody; Tuya Pal; Isabel Fan; Patricia A Shaw; Harvey A Risch; Thomas A Sellers; Ping Sun; Steven A Narod Journal: J Natl Cancer Inst Date: 2012-12-20 Impact factor: 13.506
Authors: Susan K Lutgendorf; Koen DeGeest; Caroline Y Sung; Jesusa M Arevalo; Frank Penedo; Joseph Lucci; Michael Goodheart; David Lubaroff; Donna M Farley; Anil K Sood; Steve W Cole Journal: Brain Behav Immun Date: 2008-06-11 Impact factor: 7.217
Authors: Lauren C Peres; Kara L Cushing-Haugen; Martin Köbel; Holly R Harris; Andrew Berchuck; Mary Anne Rossing; Joellen M Schildkraut; Jennifer A Doherty Journal: J Natl Cancer Inst Date: 2019-01-01 Impact factor: 13.506
Authors: Mary K Townsend; Britton Trabert; Renée T Fortner; Alan A Arslan; Julie E Buring; Brian D Carter; Graham G Giles; Sarah R Irvin; Michael E Jones; Rudolf Kaaks; Victoria A Kirsh; Synnove F Knutsen; Woon-Puay Koh; James V Lacey; Hilde Langseth; Susanna C Larsson; I-Min Lee; María Elena Martínez; Melissa A Merritt; Roger L Milne; Katie M O'Brien; Michael J Orlich; Julie R Palmer; Alpa V Patel; Ulrike Peters; Jenny N Poynter; Kim Robien; Thomas E Rohan; Lynn Rosenberg; Sven Sandin; Dale P Sandler; Leo J Schouten; V Wendy Setiawan; Anthony J Swerdlow; Giske Ursin; Piet A van den Brandt; Kala Visvanathan; Elisabete Weiderpass; Alicja Wolk; Jian-Min Yuan; Anne Zeleniuch-Jacquotte; Shelley S Tworoger; Nicolas Wentzensen Journal: Int J Epidemiol Date: 2022-06-13 Impact factor: 9.685
Authors: Xiaoman Hou; Yali Zhai; Kevin Hu; Chia-Jen Liu; Aaron Udager; Celeste L Pearce; Eric R Fearon; Kathleen R Cho Journal: Gynecol Oncol Date: 2022-04-09 Impact factor: 5.304
Authors: Susan K Lutgendorf; Frank Penedo; Michael J Goodheart; Laila Dahmoush; Jesusa M G Arevalo; Premal H Thaker; George M Slavich; Anil K Sood; Steve W Cole Journal: Cancer Date: 2020-07-21 Impact factor: 6.860